Advanced search
Publication Cover
Cancer Biology & Therapy Volume 18, 2017 - Issue 7
Submit an article Journal homepage
882
Views
3
CrossRef citations to date
0
Altmetric
Journal Club

Diagnosis, staging, and risk stratification in prostate cancer: Utilizing diagnostic tools to avoid unnecessary therapies and side effects

Louis RodgersClinical Pharmacology Program, Office of the Clinical Director, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
,
Cody J. PeerClinical Pharmacology Program, Office of the Clinical Director, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
&
William D. FiggClinical Pharmacology Program, Office of the Clinical Director, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USACorrespondence[email protected]
Pages 470-472 | Received 31 Mar 2017, Accepted 23 Apr 2017, Published online: 23 Jun 2017

References

  • Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJJ, Petros JA, Andriole GL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324(17):1156-61; PMID:1707140; https://doi.org/10.1056/NEJM199104253241702
  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66(1):7-30; PMID:26742998; https://doi.org/10.3322/caac.21332
  • Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995; 273(7):548-52; PMID:7530782; https://doi.org/10.1001/jama.1995.03520310046028
  • Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267(16):2215-20; PMID:1372942; https://doi.org/10.1001/jama.1992.03480160073037
  • Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 1998; 279(19):1542-7; PMID:9605898; https://doi.org/10.1001/jama.279.19.1542
  • Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, Yamamoto T, Mamedov A, Loblaw A. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 2015; 33(3):272-7; PMID:25512465; https://doi.org/10.1200/JCO.2014.55.1192
  • Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016; 375(15):1415-24; PMID:27626136; https://doi.org/10.1056/NEJMoa1606220
  • Alhasan AH, Scott AW, Wu JJ, Feng G, Meeks JJ, Thaxton CS, Mirkin CA. Circulating microRNA signature for the diagnosis of very high-risk prostate cancer. Proc Natl Acad Sci U S A 2016; 113(38):10655-60; PMID:27601638; https://doi.org/10.1073/pnas.1611596113
  • Hearn JW, AbuAli G, Reichard CA, Reddy CA, Magi-Galluzzi C, Chang KH, Carlson R, Rangel L, Reagan K, et al. HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: A retrospective, multicohort study. Lancet Oncol 2016; 17(10):1435-44; PMID:27575027; https://doi.org/10.1016/S1470-2045(16)30227-3
  • Simard J, Ricketts ML, Gingras S, Soucy P, Feltus FA, Melner MH. Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. Endocr Rev 2005; 26(4):525-82; PMID:15632317; https://doi.org/10.1210/er.2002-0050
  • Chang KH, Li R, Kuri B, Lotan Y, Roehrborn CG, Liu J, Vessella R, Nelson PS, Kapur P, Guo X, et al. A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 2013; 154(5):1074-84; PMID:23993097; https://doi.org/10.1016/j.cell.2013.07.029
  • Zhao SG, Chang SL, Spratt DE, Erho N, Yu M, Ashab HA, Alshalalfa M, Speers C, Tomlins SA, Davicioni E, et al. Development and validation of a 24 gene predictor of response to postoperative radiotherapy in prostate cancer: A matched, retrospective analysis. Lancet Oncol 2016; 17(11):1612-1620; PMID:27743920; https://doi.org/10.1016/S1470-2045(16)30491-0
  • Lorenzo G, Scott MA, Tew K, Hughes TJ, Zhang YJ, Liu L, Vilanova G, Gomez H. Tissue-scale, personalized modeling and simulation of prostate cancer growth. Proc Natl Acad Sci U S A 2016; 113(48):E7663-71; PMID:27856758; https://doi.org/10.1073/pnas.1615791113

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.